VERTEX PHARMACEUTICALS INC / MA Unrecognized Tax Benefits, Period Increase (Decrease)
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Unrecognized Tax Benefits, Period Increase (Decrease) of $145.90 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease · last filed 2026-02-13
- VERTEX PHARMACEUTICALS INC / MA unrecognized tax benefits, period increase (decrease) for fiscal 2025 was $145.90M, a 61.57% increase from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA unrecognized tax benefits, period increase (decrease) for fiscal 2024 was $90.30M, a 42.23% decline from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA unrecognized tax benefits, period increase (decrease) for fiscal 2023 was $156.30M, a 49.97% decline from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA unrecognized tax benefits, period increase (decrease) for fiscal 2022 was $312.40M.
| Period end | Unrecognized Tax Benefits, Period Increase (Decrease) 12 month |
|---|---|
| 2025-12-31 | $145.90M 10-K · filed 2026-02-13 |
| 2024-12-31 | $90.30M 10-K · filed 2026-02-13 |
| 2023-12-31 | $156.30M 10-K · filed 2026-02-13 |
| 2022-12-31 | $312.40M 10-K · filed 2025-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |